The Penn dermatologist told Fall Clinical 2026 that in the TOGETHER-PsO trial, tirzepatide plus ixekizumab cut blood pressure by about 8 to 10 mm Hg.
Recap by typeshit. Full story at Dermatology Times.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A short Philstar Life item on PIONEER 8, a trial of oral semaglutide. The material gives only the title, so tap through for the details.
Investseekers cites IQVIA data showing Lilly still leading the US obesity market while Novo's Wegovy line declined.
The writer argues tirzepatide does more than curb eating, pointing to its effects on appetite, fullness and blood sugar. A general explainer.
Loading…